Radiation exposure through drinking water results from naturally occurring radionuclides in drinking water sources, in particular alpha-radiation--emitting uranium, radium, and their progeny, including radon. According to the World Health Organization (WHO), when activity concentration in drinking water exceeds the recommended level of 0.5 Bq/L for gross-〈 or 1 Bq/L for gross-® activities \[simultaneously measured activity from a mixture of natural alpha \[uranium-238 (^238^U), ^234^U, thorium-232 (^232^Th), radium-226 (^226^Ra), and polonium-210 (^210^Po)\] and beta emitters \[^228^Ra and lead-210 (^210^Pb)\], radionuclide-specific concentrations should be brought into compliance with WHO guidance levels: 0.1 Bq/L for ^228^Ra; 1 Bq/L for ^223--226^Ra, ^234^U, and ^235^U; 10 Bq/L for ^238^U; 100Bq/L for radon-222 (^222^Rn), and 15 µg/L for total uranium (WHO 2004).

Ingested radionuclides are absorbed into the blood ([@r21]) and accumulate in specific tissues that they may damage. Of absorbed uranium, 66% is rapidly eliminated via urine, while the rest is distributed and stored in the kidney (12--25%), bone (10--15%), and soft tissue ([@r53]). Radium deposits mostly in the bone ([@r53]). Ingested radon gas diffuses into the stomach wall, making the stomach wall the tissue most irradiated by ingested radon because of its short half-life (3.8 days) ([@r20]).

Natural uranium induces chemical toxicity, especially nephrotoxicity, which is more harmful than radiotoxicity; whereas radium and radon are thought to induce solely radiotoxicity ([@r53]).

Although some epidemiological studies have addressed the question of the possible health effects after ingesting naturally occurring radionuclides through drinking water ([@r24], [@r25]; [@r30]; [@r43]), their results have not been summarized to date. In this commentary we discuss available epidemiological findings and evidence of possible biological effects.

Synopsis of the Available Epidemiological Evidence
==================================================

We searched the databases PubMed (<http://www.ncbi.nlm.nih.gov/pubmed>) and Scopus (<http://www.info.scopus.com>) to identify all epidemiological studies dealing with potential health effects of naturally occurring radionuclides in drinking water reported for 1970--2009. For search terms, we used combinations of the key words "health," "water," and "radioactivity." The word "health" was alternatively replaced by "epidemiology," "case control," "cohort," and "cancer." The word "radioactivity" was alternatively replaced by the names of the elements occurring in the decay chains of interest, namely uranium, thorium, protactinium, actinium, polonium, bismuth, radon, thallium, and lead. References in each paper were reviewed for additional sources. Only relevant articles published in English in peer-reviewed journals were retained. We identified 27 peer-reviewed published reports of original epidemiological studies, including studies of uranium, radium, and radon ([Table 1](#t1){ref-type="table"}).

###### 

Available epidemiological studies on the possible effects of naturally occurring radionuclides in drinking water.

  Study                                                                                      Design   Radionuclide      Average concentration in water   Outcome       No. of subjects                                                                  
  ------------------------------------------------------------------------------------------ -------- ----------------- -------------------------------- ------------- ----------------- -------------- -- ----------------------------------------- -- ----------------------------------------------------------------------------------------------------------------
  Mao et al. 1995\*                                                                                   Cross-sectional                                    U                               19.6 µg/L         Biomarkers of renal (glomerular) damage      140 cases
  Zamora et al. 1998\*                                                                                Cross-sectional                                    U                               100 µg/L          Biomarkers of renal (tubular) damage         50 cases
  Kurttio et al. 2002\*                                                                               Cross-sectional                                    U                               131 µg/L          Biomarkers of renal (tubular) damage         325 cases
  Kurttio et al. 2005\*                                                                               Cross-sectional                                    U                               124 µg/L          Biomarkers of renal (tubular) damage         288 cases
  Kurttio et al. 2006a                                                                                Cross-sectional                                    U                               25 µg/L           Biomarkers of renal (tubular) damage         193 cases
  Selden et al. 2009\*                                                                                Cross-sectional                                    U                               180 µg/L          Biomarkers of renal (tubular) damage         454 cases
  Zamora et al. 2009\*                                                                                Cross-sectional                                    U                               88 µg/L           Biomarkers of renal (tubular) damage         54 cases
  Petersen et al. 1966\*                                                                              Ecological                                         ^226^Ra                         170 mBq/L         Bone cancer mortality                        267 cases
  Bean et al. 1982\*                                                                                  Ecological                                         ^226^Ra                         \>110 mBq/L       Cancer incidence                             1,596 cases
  Lyman et al. 1985\*                                                                                 Ecological                                         ^226^Ra                         \>185 mBq/L       Leukemia incidence and mortality             873 incident/890 mortality cases
  Fuortes et al. 1990\*                                                                               Ecological                                         ^226^Ra                         NR                Leukemia incidence                           700 cases
  Hess et al. 1983                                                                                    Ecological                                         ^226^Ra                         NR                Cancer incidence                             33,928 cases
  Collman et al. 1988                                                                                 Ecological                                         ^222^Rn                         NR                Cancer mortality                             Total cancer cases NR (1,758 leukemias)
  Collman et al. 1991\*                                                                               Ecological                                         ^222^Rn                         NR                Cancer mortality                             2,706 cases (1,194 leukemias)
  Kjellberg and Wiseman 1995\*                                                                        Ecological                                         ^222^Rn                         NR                Stomach cancer incidence and mortality       NR
  Cech et al. 2007\*                                                                                  Ecological                                         ^226^Ra                         \> 110 mBq/L      Orofacial cleft defect births                167 cases
  Cech et al. 2008\*                                                                                  Ecological                                         ^226^Ra                         \> 110 mBq/L      Orofacial cleft defect births                300 cases
  Moss et al. 1995                                                                                    Case--control                                      Gross α                         300 mBq/L         Osteosarcoma incidence                       167 cases/989 controls with other cancers, matched on age, sex, and race
  Guse et al. 2002                                                                                    Case--control                                      ^226+228^Ra                     NR                Osteosarcoma incidence                       319 osteosarcoma cases/3,198 general population controls matched on age, sex, and ZIP code
  Finkelstein 1994\*                                                                                  Case--control                                      ^226^Ra                         26 mBq/L          Bone cancer mortality                        283 cases/285 controls (died of any other disease) matched on age, sex, and year of death
  Finkelstein and Kreiger 1996\*                                                                      Case--control                                      ^226^Ra                         26 mBq/L          Bone sarcoma incidence and mortality         583 cases/754 controls with (or died of) any other disease matched on age, sex, and year of death or diagnosis
  Hirunwatthanakul et al. 2006\*                                                                      Case--control                                      ^226^Ra                         NR                Digestive cancer incidence                   32 cases/138 randomly selected healthy controls
  Witmans et al. 2008\*                                                                               Case--control                                      U                               ≈ 1 µg/L          Non-Hodgkin lymphoma incidence               88 cases/132 controls matched on age and sex
  Seiler 2004                                                                                         Case--control                                      U                               ≈ 2 g/L           Leukemia incidence                           16 wells as cases/100 other community wells as controls
  Auvinen et al. 2002                                                                                 Case--cohort                                       U                               0.45 Bq/L         Leukemia incidence                           35 cases/274 controls matched on age and sex
                                                                                                                                                         ^226^Ra                         30 mBq/L                                                       
                                                                                                                                                         ^222^Rn                         500 Bq/L                                                       
  Auvinen et al. 2005                                                                                 Case--cohort                                       U                               0.45 Bq/L         Stomach cancer incidence                     107 cases/371 controls matched on age and sex
                                                                                                                                                         ^226^Ra                         30 mBq/L                                                       
                                                                                                                                                         ^222^Rn                         500 Bq/L                                                       
  Kurttio et al. 2006b                                                                                Case--cohort                                       U                               0.45 Bq/L         Urinary cancer incidence                     112 cases (61 bladder, 51 kidney)/274 controls matched on age and sex
                                                                                                                                                         ^226^Ra                         30 mBq/L                                                       
                                                                                                                                                         ^222^Rn                         500 Bq/L                                                       
  NR, not reported. \*Statistically significant increase in the health damage of interest.                                                                                                                                                              

Seven cross-sectional studies evaluated uranium in drinking water and individual biomarkers of chemotoxicity (urinary albumin, creatinine, glucose, phosphate, calcium, microglobulins, and enzymes). Overall, they reported associations between uranium concentrations in drinking water and indicators for cytotoxic damage to the proximal tubule of the kidney nephron ([@r43]; [@r54], [@r55]) and alteration of the renal absorption function ([@r24], [@r25]; [@r43]; [@r54], [@r55]). Another study reported a positive association with serum carboxy-terminal telopeptide, an indicator of bone resorption, in males ([@r26]).

When cumulative intake of uranium was estimated, null or nonsignificant associations with the studied biomarkers were found ([@r24], [@r25]; [@r30]). This may indicate that long-term uranium exposure through drinking water ingestion had no effect or that cumulative uranium intake based on self-administered questionnaires was not estimated accurately ([@r24], [@r25]). Inadequate control of confounding and insufficient power could also have been a problem.

Cancer was investigated in 10 ecological studies in the United States. These studies focused on the relationships between uranium, radium, or radon concentrations in drinking water (either in private wells or community supplies), averaged across counties or municipalities, and rates of cancer incidence or mortality measured at the same aggregation levels. In Iowa, [@r37] found that bone cancer mortality rates in people 20--29 and 60--69 years of age were significantly higher in towns with water supplies containing ^226^Ra concentration \> 110 mBq/L compared with other towns. However, the outcome used for the study (deaths due in any way to malignant neoplasm involving bone, based on death certificates codes) did not rely on a standard definition for bone cancer. [@r5] examined the incidence of various cancer sites in 28 Iowa towns, based on two national cancer survey programs. They found increased rates of bladder cancer in males, breast cancer in females, and lung cancer in both sexes in association with increasing ^226^Ra concentration in community water supplies. Bone cancer and leukemia were not studied as their rates were judged to be too unstable for analysis. In contrast, [@r29] specifically focused on leukemia incidence in 27 Florida counties. They reported a strong association with the percentage of samples from groundwater supplies that showed total radium concentration exceeding 185 mBq/L in these counties. [@r14] observed a weak and nonsignificant association between leukemia incidence and ^226^Ra concentration in water in study participants in 59 Iowa towns.

Ecological studies on radon in drinking water exhibit broadly comparable patterns. [@r18] analyzed cancer incidence in Maine counties (based on 1950--1969 National Cancer Institute statistics) and reported associations between average radon levels in water supplies and rates of all cancers combined as well as respiratory, testis, and prostate cancers in the counties. [@r10] employed a similar approach in North Carolina and reported associations with all cancers and leukemia mortality in children; however, they observed no association in adults ([@r9]). [@r23] specifically focused on stomach cancer incidence and mortality in Pennsylvania and significant associations were found, but their magnitude was not reported. No information about other risk factors for stomach cancer (e.g., food habits, smoking) was available.

Four case--control studies estimated associations between ingestion of radium via drinking water and bone cancer. Two studies were conducted in Wisconsin, based on the same cancer registry, over the periods 1979--1989 ([@r35]) and 1980--1997 ([@r17]); it is not clear whether any cases may have been included in both analyses. [@r35] reported a positive but nonsignificant association between osteosarcoma incidence and gross-〈 activity exceeding 330 mBq/L in county water supplies, whereas [@r17] reported no association with radium levels in drinking water supplies. Two case--control studies were conducted on bone cancer and ^226^Ra in water supplies at birthplace residences in Ontario, Canada, based on mortality ([@r12]) and incidence data ([@r13]). The first study reported a significant association between mortality for each subtype of bone cancers combined and ^226^Ra concentration in community water supplies or birthplace private wells. Both studies reported associations between osteosarcoma and ^226^Ra birthplace concentrations, and a significant association was reported based on a combined statistical analysis of the two studies ([@r13]). A significant association was also observed for all sarcomas. However, in this combined analysis, reconstituted (and partly simulated) lifetime ^226^Ra exposure estimates were not significantly associated with these outcomes.

A case--control study of digestive cancer incidence in Thailand reported an association with estimated oral radium consumption per day, but this was based on only 32 cases ([@r19]).

In a Saskatchewan, Canada, case--control study on non-Hodgkin lymphoma incidence, cases had higher uranium concentrations in their drinking water than controls ([@r52]). [@r42], in a case--control study of 16 leukemia cases in Fallon, Nevada, found no significant differences in well uranium or radon concentration between cases and controls.

The only cohort study investigating the association between water radioactivity and cancer incidence is one of Finnish study subjects using bedrock well water. Authors used this cohort to conduct three case--cohort studies on 107 stomach cancer cases ([@r4]), 112 urinary cancer cases ([@r27]), and 35 leukemia cases ([@r3]). No significant associations were reported, either with radionuclide concentrations (uranium, radium, and radon) in well water or with cumulative radiation doses when estimated ([@r27]). However, each study included a relatively small number of cases and therefore had only modest statistical power.

Potential reproductive toxicity of radium and radon was studied in Harris County, Texas. [@r7] reported that rates of orofacial clefts (based on birth certificates over the 1990--1994 period) were significantly higher in administrative areas (defined by postal code) with ^226^Ra concentrations exceeding 110 mBq/L than in areas with lower concentrations. Results were similar when the study was repeated in 1999--2002 using updated total radium measurements ([@r8]).

Limitations and Uncertainties
=============================

Most reviewed studies on natural radioactivity in drinking water had important limitations with regard to exposure assessment, which can bias measures of association. First, dose assessment errors can result from sampling and analysis of water. In estimating retrospective cumulative intake, authors have assumed constant uranium concentrations in water over time, although these actually vary widely depending, for instance, on carbon dioxide partial pressures, pH of the source aquifer, and season ([@r40]). Water radionuclides mitigation was considered in one study of uranium ([@r54]) but not of radium, although most were based on public water supply measurements, and water softening is known to decrease radium concentrations substantially ([@r49]). The physicochemical nature of the contaminant, that is, determining its chemical speciation in water and biological fluids, was not accounted for. This might produce misleading results as some species (e.g., calcium-uranyl-carbonato complexes) are not cytotoxic, whereas others (e.g., uranium carbonate or citrate) are ([@r39]).

Second, few studies accounted for individual water consumption patterns ([@r3]; [@r19]; [@r25]), and few have considered individual residential mobility and changes in water supplies over time \[e.g., via collection of individual residential histories ([@r13])\] although some specifically selected subjects who did not change residences ([@r3]; [@r27]). Other studies characterized water quality at residential locations either at the time of diagnosis or death ([@r17]) or at study subjects' birthplaces ([@r12]). Temporality of exposure assessment may also be an issue in cross-sectional studies of uranium chemotoxicity. Water and urine samples were obtained from participating individuals at the same time point, which would not allow judging whether exposure preceded effects.

A third and closely related issue is that most cumulative exposure assessment was based on cumulative duration of water consumption, whereas the period during which doses are delivered to target organs is a function of radionuclide intake and retention in these organs (i.e., radium or uranium sequestered in the bone). Inadequate accounting for the retention period may raise a problem of classification of the relevant dose and consequently of the dose--response magnitude. This is especially true when estimating the effects of exposures that occur during exposure windows of high sensitivity, such as fetal or child development, because of anatomical and physiological differences (e.g., higher gastrointestinal absorption of radionuclides, higher bone formation/resorption rate). Lack of information about individual differences in absorption and biokinetics could also lead to bias in the quantification of the relevant dose.

Finally, the latency period between exposure-related initiation and clinical diagnosis may be decades for some cancer but has not been accounted for (by lagging dose estimates) in most studies.

Only two studies ([@r19]; [@r54]) considered exposure to radionuclides from sources other than drinking water. However, the intake derived from food (mostly vegetables, fruit, and grains) can be \> 80% for total uranium intake and about 50% for total radium intake ([@r53]). For radon, inhalation of airborne radon released from soils or water constitutes the major route of exposure ([@r20]), and that particular route has not been considered in studies of this radionuclide. Further, coexposure to arsenic or terrestrial gamma rays, which may be higher in uranium- and radon-rich areas ([@r42]), was not considered in the reviewed studies. Collecting more data about individual lifestyle patterns (e.g., dietary patterns, smoking) would have been useful to assess potential confounding. For instance, except for [@r25], [@r27]), smoking was rarely adjusted for in studies.

Most of the reviewed studies included modest (\< 100) numbers of cases (especially for specific pathological subgroups ([@r3]; [@r42]), which limited their statistical power to detect and precisely quantify associations between health risks and radiation in drinking water. Both study sizes and duration of follow-up contributed to this limitation.

Biological Effects and Action Mechanisms
========================================

The most relevant animal studies on chronic drinking water ingestion effects were performed for uranium. Biological effects of uranium in kidneys were reported, including modifications in renal metabolism of xenobiotics ([@r44]), vitamin D homeostasis (Tissandie et al. 2007), and iron homeostasis ([@r6]). Excessive iron accumulation and apoptosis in the tubulointerstitial region and uranium-induced oxidative stress were reported ([@r28]; [@r47]). Histological lesions of renal tissue were also observed, mainly in the cortical part of the kidneys ([@r11]; [@r15]; [@r36]). [@r15] reported the lowest threshold of adverse effects for the kidney at 0.03 mg/kg/day, and this threshold was used to establish WHO guidelines for uranium in drinking water (WHO 2004). *In vitro* studies demonstrated that uranium alters the expression of genes involved in the cytochromes P450 and glutamate metabolic pathways, cell signaling and trafficking ([@r38]; [@r50]), and deregulation of the apoptotic process ([@r38]). Experimental studies indicated that *in vivo* tissue effects of uranium in kidneys are not always reflected by modifications of renal and plasma parameters. A few authors have demonstrated modifications of plasma biochemical parameters, notably urea and creatinine, despite the absence of molecular or histological effects. This may partially explain (along with the methodological limitations of epidemiological studies discussed above) the modest evidence of renal uranium effects observed in human studies. This would argue in favor of launching epidemiological and experimental studies concurrently, using the most appropriate biomarkers of adverse effects. Regarding bone, uranium induces inhibition of osteoblastic activity, resulting in bone volume decrease and healing interference ([@r16]). *In vitro* studies showed that uranium induces genomic instability and neoplastic transformation in osteoblasts ([@r33], [@r34]) and modifies oxidative metabolism and reduces bone formation ([@r46]). According to [@r38], uranium also alters the expression of the gene for osteopontin, a candidate biomarker of bone resorption and urolithiasis.

Concerning radium, most animal studies have investigated effects on bone after radium injection. Both ^226^Ra and ^228^Ra rapidly induce changes in bone structure and hematopoiesis. Bone sarcomas were found in all species tested within a life span follow-up \[Agency for Toxic Substances and Disease Registry (ATSDR) 1990\]. Leukemias were reported after ^224^Ra injection (ATSDR 1990). The major evidence concerning radium exposure effects come from epidemiological studies of radium dial painters ([@r41]), which indicated a positive dose--response relationship in humans for bone and head and neck sarcomas. Authors concluded that ^228^Ra was about twice as effective at causing bone sarcoma as ^226^Ra, whereas head carcinoma was associated only with ^226^Ra. Radium dial painters were not at increased risk of leukemia, which was unexpected given that radium accumulation in bone would be expected to affect potentially leukemic bone marrow cells. Possible explanations include nonuniformity of irradiation, lethality in target cells, or a low frequency of susceptible target cells in irradiated regions. In addition, there was no conclusive evidence of increased risks of other cancers ([@r32]).

Experimental studies that reported effects of radon-contaminated drinking water are very rare ([@r31]; [@r45]). Because of this lack of data, large uncertainties remain concerning the transit time of radon throughout the gastrointestinal tract and whole-body radon retention. These uncertainties lead to dose overestimation by greater than two orders of magnitude, depending on the model used for dose calculation ([@r22]).

Conclusion and Perspectives
===========================

Despite modest human epidemiological evidence of uranium nephrotoxicity and radium bone carcinogenicity, available studies do not clearly demonstrate the health effects of radionuclides at levels naturally encountered in drinking water. Methodological limitations (exposure assessment, possible confounders, limited sample size), affecting most reviewed studies, should be remedied in future studies.

New prospective cohorts, including potentially sensitive subpopulations (children, pregnant women) should be set in geographic regions known to have elevated concentration of radionuclides in drinking water sources (e.g., Finland and Canada for uranium, Iran and north-central states of America for radium). Exposure and biological effects assessments would be more informative if performed within the framework of prospective surveys and based on biochemical analyses of water (including chemical characterization of radionuclide contaminant) and individual biological samples (urine, blood). For uranium, urinalysis is a gold standard for exposure monitoring, whereas for radiotoxic contaminants, organ-absorbed doses must be assessed to estimate cumulative exposure. New experimental data are necessary to resolve uncertainties surrounding transit time of radon throughout the gastrointestinal tract and whole-body radon retention and thus improve precision of internal dose assessment. Measurement data should be coupled with questionnaires on water and diet consumption patterns. These questionnaires should also collect information on all potential risk factors for the health outcomes studied (e.g., smoking, occupational exposures). Residential mobility should be documented via active follow-up of individuals. To study cancer, residential exposures to radon and gamma rays should be measured in each subject's residence.

Statistical power should be calculated before launching epidemiological studies on late multifactorial pathological outcomes such as cancers. In epidemiological studies looking at biomarkers of subclinical effects, such calculations are still feasible but might be less accurate because of a lack of data relevant to assumptions used to estimate power. Some biomarkers of early adverse effect could be more sensitive indicators than disease or death; therefore, their use in epidemiological studies would require fewer subjects. However, most currently available biomarkers tend to have low sensitivity and specificity as proxy measures of adverse effects. According to [@r1], even the biomarkers considered to be the best choices for diagnosing early kidney damage (i.e., *N*-acetyl-®-glucosaminidase, human-kidney-injury-molecule-1, cystatine-c, glutathione *S*-transferase) do not meet all the criteria of a desirable biomarker, especially in terms of specificity. However, simultaneous use of complementary biomarkers can be useful to compensate for their respective limitations.

Further research should be conducted to identify biomarkers with a better specificity and sensitivity for the contaminant and/or disease. The time scale of the biomarker, exposure, and outcome to get the best matchup of the exposure--dose and dose--response relationships must be considered. Research must also be developed to relate levels of these biomarkers to a probability of future disease occurrence in order to interpret results from studies based on biomarkers of early effects in a public health perspective.

Given the extent of these challenging tasks and the need for sufficient statistical power to detect potentially subtle effects (which might have non-negligible collective impacts in view of the large numbers of people exposed), sharing of means and expertise from several research teams would probably be necessary to conduct joint studies. Ideally, this would be completed within the framework of international collaborations.
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